Lilly says about 70% of patients taking tirzepatide experienced an adverse event
Eli Lilly shared more detailed data about its GIP/GLP-1 receptor agonist tirzepatide on Thursday at the European Association for the Study of Diabetes annual meeting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.